World Contraceptives Market - Opportunities and Forecasts, 2014 - 2022

  • ID: 3773626
  • Report
  • Region: Global
  • 155 pages
  • Allied Analytics LLP
1 of 4
Contraception is the deliberate use of artificial methods to prevent pregnancy by interfering with the normal process of fertilization, ovulation, and implantation. The most common form of contraception, popularly known as fertility control or birth control, is a barrier method. It is available in two major forms in the market, namely, contraceptive drugs and devices. Contraceptive drugs include oral (pills), topical, and injectable contraceptives. Whereas, contraceptive devices include condom, Intrauterine devices (IUD), vaginal ring, implant, patch, diaphragms, sponges, and others. The major form of artificial contraception is the barrier method, especially condoms.

The world contraceptives market is expected to garner $43,812 million by 2022 from $28,175 million in 2015, registering a CAGR of 6.4% from 2016 to 2022. Increase in focus to prevent unwanted pregnancies, the incidence of STIs, and technological advancements in contraceptive methods majorly drive the market. Other birth control factors, such as family planning to improve the quality of life for both women and children and growth in adoption of modern contraceptives to control population have contributed majorly to the market growth. However, health risks associated with contraceptives, lack of social acceptance, and rise in prevalence of infertility among women hamper the Contraceptive market growth.

The world contraceptives market is segmented based on product, age group, education, end user, and geography. Based on product, the market is further segmented into contraceptive drugs and devices. Contraceptive drugs are further categorized into oral pills, topical, and injectable contraceptives. Among these, oral pills dominate the overall contraceptive drugs market, owing to their high success rate and increase in use as emergency contraceptive pills, also known as “morning pill”. In addition, contraceptive devices are further categorized into condom, IUD, vaginal ring, implant, patch, sponges, diaphragms, and others. Male condoms dominate the overall contraceptive device market due to the associated advantages such as cost-effective, fewer side effects, and ease of use.

Contraceptive market is further categorized by various age groups-15-24, 25-34, 35-44 and above 44 years, depending upon the usage and revenue generated by these age groups. On the basis of education the contraceptive market is further categorized into less than high school, high school graduate, college graduate, and other college degrees. Based on end user, the contraceptive market is segmented into household, hospitals, and, clinics. The world contraceptive market is analyzed based on four regions, namely North America, Europe, Asia-Pacific, and LAMEA. These regions are further categorized into their respective countries. In 2015, North America accounted for the largest share in the contraceptive market due to factors, such as product innovations, large number of public awareness programs, and growth in incidence of unwanted pregnancies among teenagers. U.S. majorly contributes for the remarkable growth in North America especially due to the large consumer base for advanced contraception. In addition, the Asia-Pacific region is expected to offer lucrative opportunities to market players, due to increase in focus of key players to expand in the emerging economies, improvement of healthcare infrastructure, and growth in population in populace countries such as China and India.

Market players have adopted product launch and acquisition as their key strategies to sustain the intense competition in the contraceptives market. For instance, in May 2016, Allergan launched levonorgestrel-releasing intrauterine system (LILETTA) 52 mg, a hormone-releasing system placed in woman's uterus to prevent pregnancy for up to 3 years with effectiveness of more than 99%. Moreover, Actavis plc acquired Allergan, Inc. (U.S.), a pharmaceutical company to expand its product portfolio of women’s health and provide a robust platform for future product development.

KEY MARKET BENEFITS

This report provides the quantitative analysis of the current market and estimations for the period of 2014-2022 to identify the prevailing market opportunities.
This report provides an extensive analysis of the current and emerging market trends and dynamics in the world contraceptives market.
The market is analyzed based on various regions, namely, North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided in the report.
In-depth analyses of current research and developments within contraceptives market are provided along with key market dynamic factors to understand the market dynamics.
Key market players in the market are profiled in this report along with detailed analysis of their strategies.

KEY MARKET SEGMENTS:

The world contraceptives market is segmented into product, age group, education, end user, and geography.

By Product

Drugs
Oral Contraceptive Pills
Injectable Contraceptives
Topical Contraceptives
Devices
Condoms
Female Condoms
Male Condoms
Intrauterine devices (IUDs)
Hormonal IUDs
Copper IUDs
Diaphragms
Sponges
Patches
Implants
Vaginal Rings
Others

AGE GROUP

15-24 years
25-34 years
35-44 years
Above 44 years

BY END USER

Less than high school
High school graduate
College graduate
Other college degrees

By End User

Household
Hospitals
Clinics

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Others
Asia-Pacific
Japan
China
Australia
India
Others
LAMEA
Japan
China
Australia
India
Others

KEY PLAYERS

The Female Health Company
Teva Pharmaceutical Industries Limited
Allergan plc
Bayer AG
Pfizer, Inc.
The Cooper Companies Inc.
Ansell LTD.
Mayer Laboratories
Merck & Co., Inc.
Church & Dwight, Co., Inc.

Other players in the value chain include (profiles not included in the report)

Reckitt Benckiser Plc
Warner Chilcott Company
BioSante Pharmaceuticals Inc.
Agile Therapeutics Inc.
HLL Lifecare Limited
MANKIND Pharmaceuticals
TTK HealthCare
Boehringer Ingelheim GmbH
Watson Pharmaceuticals, Inc.
V-Care Pharma Pvt. Ltd.
Vardhman Life care pvt. Ltd.
Cipla Limited.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitutes
3.3.5 High intensity of rivalry
3.4 Regulatory scenario
3.4.1 Government regulations across countries
3.4.2 Womens preventive services guideline
3.4.3 FDA-approved contraceptives method
3.4.4 The Affordable care act contraceptive coverage and advantages
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Rise in need to reduce unwanted pregnancy
3.5.1.2 Increasing awareness for contraceptives worldwide
3.5.1.3 Rising usage of oral contraceptives as preferred method to avoid unplanned pregnancy
3.5.1.4 Technological advancements in contraceptive methods
3.5.1.5 Upsurge in government and NGO initiatives promoting contraceptives
3.5.1.6 Increasing awareness about STDs
3.5.2 Restraints
3.5.2.1 Health risks associated with the use of contraceptive methods
3.5.2.2 Lack of social acceptance
3.5.3 Opportunities
3.5.3.1 Presence of large unmet contraceptive needs in emerging Asian and African Economies

CHAPTER 4 WORLD CONTRACEPTIVES MARKET, BY PRODUCT, 2014-2022
4.1 Overview
4.1.1 Market size and forecast
4.2 Drugs
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Oral contraceptive or pills
4.2.4.1 Market size and forecast
4.2.5 Injectable contraceptives
4.2.5.1 Market size and forecast
4.2.6 Topical contraceptives
4.2.6.1 Market size and forecast
4.3 Contraceptive devices
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Condoms
4.3.4.1 Market size and forecast
4.3.4.2 Female condoms
4.3.4.2.1 MARKET SIZE AND FORECAST
4.3.4.3 Male condoms
4.3.4.3.1 MARKET SIZE AND FORECAST
4.3.5 Intrauterine devices (IUD)
4.3.5.1 Market size and forecast
4.3.5.2 Hormonal IUDs
4.3.5.2.1 MARKET SIZE AND FORECAST
4.3.5.3 Copper IUDs
4.3.5.3.1 MARKET SIZE AND FORECAST
4.3.6 Contraceptive diaphragms
4.3.6.1 Market size and forecast
4.3.7 Contraceptive sponges
4.3.7.1 Market size and forecast
4.3.8 Contraceptive patches
4.3.8.1 Market size and forecast
4.3.9 Sub-dermal contraceptive implants
4.3.9.1 Market size and forecast
4.3.10 Contraceptive vaginal rings
4.3.10.1 Market size and forecast
4.3.11 Others
4.3.11.1 Market size and forecast

CHAPTER 5 WORLD CONTRACEPTIVES MARKET, BY AGE GROUP
5.1 Overview
5.1.1 Market size and forecast
5.2 15-24 years
5.2.1 Market size and forecast
5.3 25-34 years
5.3.1 Market size and forecast
5.4 35-44 years
5.4.1 Market size and forecast
5.5 Above 44 years
5.5.1 Market size and forecast

CHAPTER 6 WORLD CONTRACEPTIVES MARKET, BY EDUCATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Less than high school
6.2.1 Market size and forecast
6.3 High school graduate
6.3.1 Market size and forecast
6.4 College graduate
6.4.1 Market size and forecast
6.5 Other college degrees
6.5.1 Market size and forecast

CHAPTER 7 WORLD CONTRACEPTIVES MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Household
7.2.1 Market size and forecast
7.3 Hospitals
7.3.1 Market size and forecast
7.4 Clinics
7.4.1 Market size and forecast

CHAPTER 8 CONTRACEPTIVES MARKET, BY GEOGRAPHY, 2014-2022
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast
8.2.3.1 U.S. contraceptives market
8.2.3.2 Canada contraceptives market
8.2.3.3 Mexico contraceptives market
8.3 Europe
8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast
8.3.3.1 Germany contraceptives market
8.3.3.2 France contraceptives market
8.3.3.3 U.K. contraceptives market
8.3.3.4 Rest of Europe contraceptives market
8.4 Asia-Pacific
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
8.4.3.1 Japan contraceptives market
8.4.3.2 China contraceptives market
8.4.3.3 Australia contraceptives market
8.4.3.4 India contraceptives market
8.4.3.5 Rest of Asia Pacific contraceptives market
8.5 LAMEA
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast
8.5.3.1 Brazil contraceptives market
8.5.3.2 Turkey contraceptives market
8.5.3.3 Venezuela contraceptives market
8.5.3.4 South Africa contraceptives market
8.5.3.5 Rest of LAMEA contraceptives market

CHAPTER 9 COMPANY PROFILES
9.1 Mylan N.V.
9.1.1 Company overview
9.1.2 Operating business segments
9.1.3 Business performance
9.1.4 Key strategic moves & developments
9.2 Ansell Limited
9.2.1 Company overview
9.2.2 Operating business segments
9.2.3 Business performance
9.2.4 Key strategic moves & developments
9.3 Bayer AG
9.3.1 Company overview
9.3.2 Operating business segments
9.3.3 Business performance
9.3.4 Key strategic moves & developments
9.4 Church & Dwight Co., Inc.
9.4.1 Company overview
9.4.2 Operating business segments
9.4.3 Business performance
9.5 Merck & Co., Inc.
9.5.1 Company overview
9.5.2 Operating business segments
9.5.3 Business performance
9.6 Pfizer Inc.
9.6.1 Company overview
9.6.2 Operating business segments
9.6.3 Business performance
9.6.4 Key strategic moves & developments
9.7 Teva Pharmaceutical Industries Limited
9.7.1 Company overview
9.7.2 Operating business segments
9.7.3 Business performance
9.7.4 Key strategic moves & developments
9.8 The Cooper Companies, Inc.
9.8.1 Company overview
9.8.2 Operating business segments
9.8.3 Business performance
9.8.4 Key strategic moves & developments
9.9 The Female Health Company
9.9.1 Company overview
9.9.2 Operating business segments
9.9.3 Business performance
9.9.4 Key strategic moves & developments
9.10 Mayer Laboratories, Inc.
9.10.1 Company overview
Table 1 World Contraceptives Market, By Product Type, 20142022 ($Million)
Table 2 World Contraceptives Market, By Drug Type, 20142022 ($Million)
Table 3 World Contraceptives Market, By Device Type, 20142022 ($Million)
Table 4 World Condom Market, By Type, 2014 - 2022 ($Million)
Table 5 World Female Condoms Market, By Region, 2014 - 2022 ($Million)
Table 6 World Male Condoms Market, By Region, 2014 - 2022 ($Million)
Table 7 World Intrauterine Devices (Iud) Market, By Type 2014 2022 ($Million)
Table 8 World Hormonal Iuds Market, By Region, 2014 - 2022 ($Million)
Table 9 World Copper Iuds Market, By Region, 2014 - 2022 ($Million)
Table 10 World Contraceptives Market, By Age Group, 20142022 ($Million)
Table 11 World Contraceptives Market, By Education, 20142022 ($Million)
Table 12 World Contraceptives Market, By End USer, 20142022 ($Million)
Table 13 Contraceptives Market For Household, By Region, 20142022 ($Million)
Table 14 Contraceptives Market For Hospitals, By Region, 20142022 ($Million)
Table 15 Contraceptives Market For Clinics, By Region, 20142022 ($Million)
Table 16 Contraceptives Market, By Geography, 20142022 ($Million)
Table 17 North America: Contraceptives Market, By Country, 20142022 ($Million)
Table 18 North America: Contraceptives Market, By Drug Type, 2014-2022 ($Million)
Table 19 North America: Contraceptives Market, By Devices Type, 2014-2022 ($Million)
Table 20 North America: Contraceptives Market, By Age Group, 2014-2022 ($Million)
Table 21 North America: Contraceptives Market, By Education, 2014-2022 ($Million)
Table 22 U.S. Contraceptives Market, By Product Type, 20142022 ($Million)
Table 23 Canada Contraceptives Market, By Product Type, 20142022 ($Million)
Table 24 Mexico Contraceptives Market, By Product Type, 20142022 ($Million)
Table 25 Europe: Contraceptives Market, By Country, 20142022 ($Million)
Table 26 Europe: Contraceptives Market, By Drug Type, 2014-2022 ($Million)
Table 27 Europe: Contraceptives Market, By Devices Type, 2014-2022 ($Million)
Table 28 Europe: Contraceptives Market, By Age Group, 2014-2022 ($Million)
Table 29 Europe: Contraceptives Market, By Education, 2014-2022 ($Million)
Table 30 Germany Contraceptives Market, By Product Type, 20142022 ($Million)
Table 31 France Contraceptives Market, By Product Type, 20142022 ($Million)
Table 32 U.K. Contraceptives Market, By Product Type, 20142022 ($Million)
Table 33 Rest Of Europe Contraceptives Market, By Product Type, 20142022 ($Million)
Table 34 Asia Pacific: Contraceptives Market, By Country, 20142022 ($Million)
Table 35 Asia Pacific: Contraceptives Market, By Drug Type, 2014-2022 ($Million)
Table 36 Asia Pacific: Contraceptives Market, By Devices Type, 2014-2022 ($Million)
Table 37 Asia Pacific: Contraceptives Market, By Age Group, 2014-2022 ($Million)
Table 38 Asia Pacific: Contraceptives Market, By Education, 2014-2022 ($Million)
Table 39 Japan Contraceptives Market, By Product Type, 20142022 ($Million)
Table 40 China Contraceptives Market, By Product Type, 20142022 ($Million)
Table 41 Australia Contraceptives Market, By Product Type, 20142022 ($Million)
Table 42 India Contraceptives Market, By Product Type, 20142022 ($Million)
Table 43 Rest Of Asia Pacific Contraceptives Market, By Product Type, 20142022 ($Million)
Table 44 Lamea: Contraceptives Market, By Country, 20142022 ($Million)
Table 45 Lamea: Contraceptives Market, By Drug Type, 2014-2022 ($Million)
Table 46 Lamea: Contraceptives Market, By Devices Type, 2014-2022 ($Million)
Table 47 Lamea: Contraceptives Market, By Age Group, 2014-2022 ($Million)
Table 48 Lamea: Contraceptives Market, By Education, 2014-2022 ($Million)
Table 49 Brazil Contraceptives Market, By Product Type, 20142022 ($Million)
Table 50 Turkey Contraceptives Market, By Product Type, 20142022 ($Million)
Table 51 Venezuela Contraceptives Market, By Product Type, 20142022 ($Million)
Table 52 South Africa Contraceptives Market, By Product Type, 20142022 ($Million)
Table 53 Rest Of Lamea Contraceptives Market, By Product Type, 20142022 ($Million)
Table 54 Allergan - Company Snapshot
Table 55 Allergan - Operating Segments
Table 56 Ansell Limited - Company Snapshot
Table 57 Ansell Limited - Operating Segments
Table 58 Bayer - Company Snapshot
Table 59 Bayer - Operating Segments
Table 60 Church & Dwight - Company Snapshot
Table 61 Church & Dwight - Operating Segments
Table 62 Merck - Company Snapshot
Table 63 Merck - Product Categories
Table 64 Pfizer - Company Snapshot
Table 65 Pfizer - Operating Segments
Table 66 Teva Pharmaceutical - Company Snapshot
Table 67 Teva Pharmaceutical - Operating Segments
Table 68 Cooper - Company Snapshot
Table 69 Cooper: Operating Segments
Table 70 Fhc - Company Snapshot
Table 71 Mayer - Company Snapshot
Fig. 1 Market Segmentation For Contraceptives Market
Fig. 2 Top Investment Pockets
Fig. 3 Top Winning Strategies: Percentage Distribution (20142016)
Fig. 4 Top Winning Strategies: Nature And Type
Fig. 5 Porters Five Forces Analysis
Fig. 6 Privately Insured Women Percentage Who Paid $0 For The Contraceptive Method
Fig. 7 Top Impacting Factors
Fig. 8 Percentage Of Pregnancy By Intention
Fig. 9 World Contraceptives Market, By Product Type, 2015 (%)
Fig. 10 World Oral Contraceptives Or Pills Market, 2014 - 2022 ($Million)
Fig. 11 World Contraceptives Injectables Market, 2014 - 2022 ($Million)
Fig. 12 World Topical Contraceptives Market, 2014 - 2022 ($Million)
Fig. 13 World Contraceptive Diaphragm Market, 2014 - 2022 ($Million)
Fig. 14 World Contraceptive Sponge Market, 2014 - 2022 ($Million)
Fig. 15 World Contraceptive Patch Market, 2014 - 2022 ($Million)
Fig. 16 World Sub-Dermal Contraceptive Implants Market, 2014 - 2022 ($Million)
Fig. 17 World Vaginal Rings Market, 2014 - 2022 ($Million)
Fig. 18 World Other Contraceptive Devices Market, 2014 - 2022 ($Million)
Fig. 19 World Contraceptives Market For 15-24 Years, 2014 - 2022 ($Million)
Fig. 20 World Contraceptives Market For 25-34 Years, 2014 - 2022 ($Million)
Fig. 21 World Contraceptives Market For 35-44 Years, 2014 - 2022 ($Million)
Fig. 22 World Contraceptives Market For Above 44 Years, 2014 - 2022 ($Million)
Fig. 23 World Contraceptives Market For Less Than High School, 2014 - 2022 ($Million)
Fig. 24 World Contraceptives Market For High School Graduate, 2014 - 2022 ($Million)
Fig. 25 World Contraceptives Market For College Graduate, 2014 - 2022 ($Million)
Fig. 26 World Contraceptives Market For Other College Degrees, 2014 - 2022 ($Million)
Fig. 27 World Contraceptives Market, By End USer, 2015 (%)
Fig. 28 Contraceptives Market For Household, By Region, 2014 - 2022 (%)
Fig. 29 Contraceptives Market For Hospital, By Region, 2014 - 2022 (%)
Fig. 30 Contraceptives Market For Clinics, By Region, 2014 - 2022 (%)
Fig. 31 More Effective Contraceptives USe, By Country
Fig. 32 World Contraceptives Market, By Region, 2015 (%)
Fig. 33 North America Contraceptives Market, By Country, 2014 - 2022 (%)
Fig. 34 U.K.: Contraception USe By Women, By Age, 20082009
Fig. 35 Europe Contraceptives Market, By Country, 2014 - 2022 (%)
Fig. 36 Asia Pacific Contraceptives Market, By Country, 2014 - 2022 (%)
Fig. 37 Lamea Contraceptives Market, By Country, 2014 - 2022 (%)
Fig. 38 Allergan: Net Sales, 20132015 ($Million)
Fig. 39 Allergan: Net Sales, By Business Segment, 2015 (%)
Fig. 40 Allergan: Strategy Share, 20142016 (%)
Fig. 41 Ansell Limited: Net Sales, 20132015 ($Million)
Fig. 42 Ansell Limited: Net Sales, By Business Segment, 2015 (%)
Fig. 43 Ansell Limited: Net Sales, By Geography, 2015 (%)
Fig. 44 Ansell Limited: Strategy Share, 20152016 (%)
Fig. 45 Bayer: Net Sales, 20132015 ($Million)
Fig. 46 Bayer: Net Sales, By Segments, 2015 (%)
Fig. 47 Bayer: Net Sales, By Geography, 2015(%)
Fig. 48 Church & Dwight: Net Sales, 20132015 ($Million)
Fig. 49 Church & Dwight: Net Sales, By Segment, 2015, (%)
Fig. 50 Merck: Net Sales, 20132015 ($Million)
Fig. 51 Merck: Net Sales, By Business Segment, 2015 (%)
Fig. 52 Merck: Net Sales, By Geography, 2015 (%)
Fig. 53 Pfizer: Net Sales, 20132015 ($Million)
Fig. 54 Pfizer: Net Sales, By Segment, 2015 (%)
Fig. 55 Pfizer: Net Sales, By Geography, 2015 (%)
Fig. 56 Pfizer: Strategy Share, (%)
Fig. 57 Teva Pharmaceutical: Net Sales, 20132015 ($Million)
Fig. 58 Teva Pharmaceutical: Net Sales, By Business Segment, 2015 (%)
Fig. 59 Teva Pharmaceutical: Net Sales, By Geography, 2015 (%)
Fig. 60 Cooper: Net Sales, 20132015 ($Million)
Fig. 61 Cooper: Net Sales, By Business Segment, 2015 ($Million)
Fig. 62 Cooper: Net Sales, By Geography, 2015, (%)
Fig. 63 Fhc: Net Sales, 20132015 ($Million)
Fig. 64 Fhc: Net Sales, By Geography, 2015 ($Million)
Fig. 65 Fhc: Strategy Share (%), 20142016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Contraceptives Market Report, forecasts that the global market is expected to garner $43,812 million by 2022, registering a CAGR of 6.4% during the period 2016-2022. Contraceptive drugs are expected to dominate the market throughout the study period. North America would continue its lead, accounting for more than one-third share of the world contraceptive market in 2015.

Advent of advanced contraceptive methods, emergency contraceptives method especially for teenagers, and increase in awareness towards sexually transmitted infections (STIs), are the major factors responsible for the growth of contraceptives market. Growth in popularity of female condoms, custom-fit condoms, and other novel products have fueled the contraceptive demand, especially in the developed regions. Furthermore, rise in adoption for modern contraceptives in the developing economies contribute to the significant growth in the world contraceptives market. However, associated risks, sociocultural influences of contraceptives, and side effects such as infertility resulting from the use of contraception are the major impediments to the market growth.

Oral contraceptive drugs or oral contraceptive pills segment accounted for over 85% share in the overall contraceptive drugs market in 2015. Oral pills are the most common type of reversible contraception used globally. High effectiveness and convenience in comparison to contraceptive devices, particularly implants have made it a preferred mode of contraception. Also, the large consumer base and government initiatives to cater the unmet need of contraception further boosts the market growth. Injectable contraceptives is the fastest growing segment in the global market, and is estimated to register a CAGR of 7.2% during the forecast period due to rise in awareness among individuals and growth in population.

Condoms is expected to dominate the overall contraceptives device market throughout the analysis period, due to the increase in demand in developed as well as developing economies. Male condoms are more popular than female condoms; thereby significantly boosting the growth of the overall contraceptive market. The increase in popularity of male condoms is attributed to their easy accessibility, ease-of-use, and wide acceptance across various regions. Furthermore, intrauterine (IUD) segment is anticipated to exhibit the highest growth, registering a CAGR of 10.1% during the forecast period, owing to their effectiveness in prevention of unwanted pregnancies for almost 1012 years after insertion in the body and transmission of STDs.

Based on age group, women ranging between 15 and 24 years, are the major contributors to generate highest revenue in the world contraceptive market. This is owing to the increased usage of contraceptives among the teenagers and early maturity among the teenage girls, raising the demand for contraceptives. However, women aged above 44, are the least contributor to the market growth due to the menopause in women at the age 44 and above.

The North American region accounted for majority of the share of the world contraceptives market in 2015. The North American contraceptive market is expected to maintain its lead throughout the forecast period due to increase in awareness among the population, rise in adoption of modern contraceptives, and increase in prevalence of sexually transmitted diseases such as HIV/AIDS. The U.S. contraceptive market accounts for the largest share in the overall North America contraceptive market. Asia-Pacific region is expected to grow at the fastest pace during the study period, owing to high population base, and proactive governmental bodies that focus on birth control. Moreover, technological advancements and cost-effective contraceptive products in these regions offer lucrative opportunities to contraceptive manufacturers.

Key Findings of the Study:

Oral contraceptive drugs or pills was the leading segment in the overall contraceptive market, accounting for $16,997 million in 2015, and is projected to grow at a CAGR of 5.6% during the forecast period.
Contraceptive devices segment is expected to grow at a CAGR of 7.8%, owing to the increased demand for the prevention of unwanted pregnancies in home settings.
Intrauterine (IUD) segment is projected to grow at a significant CAGR of 10.1% during the analysis period.
Condom segment generated the highest revenue in 2015, accounted for $6,053 million in the world contraceptive devices market and projected to retain its dominance during the analysis period.
Vaginal ring is estimated to grow at significant rate of 10.0% during the forecast period from 2016 to 2022.
Contraceptive patch is poised to grow at a remarkable CAGR of 8.8% during the analysis period.
North America is the major shareholder, accounting for about 32% share of the world contraceptives market.
Germany accounted for around one-fourth share of the European contraceptives market in 2015.

The key players in the contraceptives market are highly focused to expand their business operations in the fast-growing emerging countries and launched new products to increase their market shares. The key players profiled in this report include The Female Health Company, Teva Pharmaceutical Industries Limited, Allergan plc, Bayer AG, Pfizer, Inc., Cooper Companies, INC., Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc. Other players in the value chain include Reckitt Benckiser Plc, BioSante Pharmaceuticals Inc., Warner Chilcott Company, Agile Therapeutics Inc., MANKIND Pharmaceuticals, HLL Lifecare Limited, TTK HealthCare, Watson Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, V-Care Pharma Pvt. Ltd., Vardhman Life care pvt. Ltd., Cipla Limited and others.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll